Equities Analysts Set Expectations for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Caribou Biosciences in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $16.92 per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million.

Several other analysts have also recently issued reports on CRBU. Bank of America cut their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday. Citigroup cut their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Performance

Shares of CRBU stock opened at $1.72 on Wednesday. The stock has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $2.00. Caribou Biosciences has a 52-week low of $1.50 and a 52-week high of $8.33. The firm has a market capitalization of $155.75 million, a PE ratio of -1.04 and a beta of 2.34.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CRBU. Bank of New York Mellon Corp grew its position in Caribou Biosciences by 14.1% in the second quarter. Bank of New York Mellon Corp now owns 308,273 shares of the company’s stock worth $506,000 after acquiring an additional 38,098 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Caribou Biosciences by 15.2% in the second quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after acquiring an additional 16,530 shares during the period. Bruce & Co. Inc. boosted its stake in shares of Caribou Biosciences by 50.0% during the 2nd quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $492,000 after purchasing an additional 100,000 shares during the period. Dimensional Fund Advisors LP grew its holdings in Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after purchasing an additional 536,162 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Caribou Biosciences in the 2nd quarter worth about $2,432,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.